Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug;18(8):1510-5.
doi: 10.1038/oby.2010.90. Epub 2010 Apr 15.

Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction

Affiliations

Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction

Faidon Magkos et al. Obesity (Silver Spring). 2010 Aug.

Abstract

Aim of this study was to determine whether an increase in adiposity, without a concomitant increase in intrahepatic triglyceride (IHTG) content, is associated with a deterioration in metabolic function. To this end, multiorgan insulin sensitivity, assessed by using a two-stage hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopically labeled tracer infusion, and very low-density lipoprotein (VLDL) kinetics, assessed by using stable isotopically labeled tracer infusion and mathematical modeling, were determined in 10 subjects with class I obesity (BMI: 31.6 +/- 0.3 kg/m(2); 37 +/- 2% body fat; visceral adipose tissue (VAT): 1,225 +/- 144 cm(3)) and 10 subjects with class III obesity (BMI: 41.5 +/- 0.5 kg/m(2); 43 +/- 2% body fat; VAT: 2,121 +/- 378 cm(3)), matched on age, sex, and IHTG content (14 +/- 4 and 14 +/- 3%, respectively). No differences between class I and class III obese groups were detected in insulin-mediated suppression of palmitate (67 +/- 3 and 65 +/- 3%, respectively; P = 0.635) and glucose (67 +/- 3 and 73 +/- 5%, respectively; P = 0.348) rates of appearance in plasma, and the insulin-mediated increase in glucose disposal (218 +/- 18 and 193 +/- 30%, respectively; P = 0.489). In addition, no differences between class I and class III obese groups were detected in secretion rates of VLDL-triglyceride (6.5 +/- 1.0 and 6.0 +/- 1.4 micromol/l x min, respectively; P = 0.787) and VLDL-apolipoprotein B-100 (0.40 +/- 0.05 and 0.41 +/- 0.04 nmol/l x min, respectively; P = 0.866), and plasma clearance rates of VLDL-triglyceride (31 (16-59) and 29 (18-46) ml/min, respectively; P = 0.888) and VLDL-apolipoprotein B-100 (15 (11-19) and 17 (11-25) ml/min, respectively; P = 0.608). We conclude that increased adiposity without a concomitant increase in IHTG content does not cause additional abnormalities in adipose tissue, skeletal muscle, and hepatic insulin sensitivity, or VLDL metabolism.

PubMed Disclaimer

Conflict of interest statement

Disclosure: There are no financial conflicts with the subject matter or materials discussed in this manuscript with any of the authors.

Figures

Figure 1
Figure 1
Insulin-induced suppression of glycerol, palmitate and glucose rates of appearance (Ra) and insulin-induced stimulation of glucose rate of disappearance (Rd) in subjects with class I and III obesity, matched on intrahepatic triglyceride content. Values are means ± SEM. There are no significant differences between groups.
Figure 2
Figure 2
Basal very low density lipoprotein (VLDL) triglyceride (TG) and apolipoprotein B-100 (apoB-100) kinetics in subjects with class I and III obesity, matched on intrahepatic triglyceride content. Values are means ± SEM, except for plasma clearance rates which are means and 95% confidence intervals. There are no significant differences between groups.

References

    1. Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology. 2002;123:882–932. - PubMed
    1. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. Obes Res. 1998;6 Suppl 2:51S–209S. - PubMed
    1. Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr. 2000;72:694–701. - PubMed
    1. Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heymsfield SB. How useful is body mass index for comparison of body fatness across, age, sex, and ethnic groups? Am J Epidemiol. 1996;143:228–239. - PubMed
    1. Colditz GA, Willett WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol. 1990;132:501–513. - PubMed

Publication types